PURPOSE: The purpose of this study was to design a well-characterized liposomal carrier system for multivalent antigen presentation in order to activate T cells. METHODS: MHC class II molecules were loaded with peptide and subsequently reconstituted into liposomes. A FACS assay was developed to monitor peptide loading and MHC class II incorporation in the liposomes. For in vitro testing of the resulting MHC class II/peptide liposomes, a T cell hybridoma assay was employed. RESULTS: The FACS assay provided a qualitative means to visualize the amount of incorporated MHC class II and peptide molecules that were oriented in the appropriate way for antigen presentation to the T cells. Interestingly, when MHC class II molecules were loaded with the appropriate peptide prior to liposome incorporation, such liposomes were fully capable of inducing IL-2 production of a T cell hybridoma. CONCLUSIONS: This is the first article showing that MHC class II/peptide liposomes can serve as 'artificial antigen presenting cells' for activation of a CD4+ T cell hybridoma. As compared to soluble MHC class II/peptide complexes, the multivalency of liposomal complexes may be an important advantage when studying possible applications in immunotherapy.
PURPOSE: The purpose of this study was to design a well-characterized liposomal carrier system for multivalent antigen presentation in order to activate T cells. METHODS: MHC class II molecules were loaded with peptide and subsequently reconstituted into liposomes. A FACS assay was developed to monitor peptide loading and MHC class II incorporation in the liposomes. For in vitro testing of the resulting MHC class II/peptide liposomes, a T cell hybridoma assay was employed. RESULTS: The FACS assay provided a qualitative means to visualize the amount of incorporated MHC class II and peptide molecules that were oriented in the appropriate way for antigen presentation to the T cells. Interestingly, when MHC class II molecules were loaded with the appropriate peptide prior to liposome incorporation, such liposomes were fully capable of inducing IL-2 production of a T cell hybridoma. CONCLUSIONS: This is the first article showing that MHC class II/peptide liposomes can serve as 'artificial antigen presenting cells' for activation of a CD4+ T cell hybridoma. As compared to soluble MHC class II/peptide complexes, the multivalency of liposomal complexes may be an important advantage when studying possible applications in immunotherapy.
Authors: I Joosten; M H Wauben; M C Holewijn; K Reske; L O Pedersen; C F Roosenboom; E J Hensen; W van Eden; S Buus Journal: Int Immunol Date: 1994-05 Impact factor: 4.823
Authors: A J van Rensen; L S Taams; M C Grosfeld-Stulemeyer; W van Eden; D J Crommelin; M H Wauben Journal: Pharm Res Date: 2000-06 Impact factor: 4.200
Authors: Christian Schütz; Mathias Oelke; Jonathan P Schneck; Andreas Mackensen; Martin Fleck Journal: Immunotherapy Date: 2010-07 Impact factor: 4.196